Thermo Fisher Scientific (TMO) Cash & Equivalents (2009 - 2026)

Thermo Fisher Scientific has reported Cash & Equivalents for 18 years, with the latest figure at $4.1 billion in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $4.1 billion, down 11.19% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.1 billion (down 11.19% YoY), and the FY2025 annual result was $9.9 billion, up 145.75% from the prior year.
• Cash & Equivalents advanced to $4.1 billion in Q2 2026, from $3.3 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.9 billion in Q4 2025 and troughed at $1.9 billion in Q3 2022.
• A 5-year average of $4.8 billion and a median of $4.1 billion in 2025 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 75.73%; it then jumped 145.75% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $8.5 billion in 2022, then retreated by 5.24% to $8.1 billion in 2023, then plunged by 50.37% to $4.0 billion in 2024, then soared by 145.75% to $9.9 billion in 2025, then plunged by 58.75% to $4.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $4.1 billion in Q2 2026, $3.3 billion in Q1 2026, and $9.9 billion in Q4 2025.